Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009719310 | Cervix | CC | intrinsic apoptotic signaling pathway | 85/2311 | 288/18723 | 4.56e-15 | 6.46e-12 | 85 |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:005254710 | Cervix | CC | regulation of peptidase activity | 112/2311 | 461/18723 | 6.70e-13 | 3.08e-10 | 112 |
GO:004586210 | Cervix | CC | positive regulation of proteolysis | 95/2311 | 372/18723 | 1.84e-12 | 6.86e-10 | 95 |
GO:005254810 | Cervix | CC | regulation of endopeptidase activity | 103/2311 | 432/18723 | 1.89e-11 | 5.14e-09 | 103 |
GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
GO:001095210 | Cervix | CC | positive regulation of peptidase activity | 54/2311 | 197/18723 | 8.06e-09 | 6.99e-07 | 54 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:200011610 | Cervix | CC | regulation of cysteine-type endopeptidase activity | 61/2311 | 235/18723 | 8.69e-09 | 7.22e-07 | 61 |
GO:004328110 | Cervix | CC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 55/2311 | 209/18723 | 2.77e-08 | 1.95e-06 | 55 |
GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
GO:000030210 | Cervix | CC | response to reactive oxygen species | 56/2311 | 222/18723 | 1.00e-07 | 5.25e-06 | 56 |
GO:006219710 | Cervix | CC | cellular response to chemical stress | 76/2311 | 337/18723 | 1.01e-07 | 5.25e-06 | 76 |
GO:001095010 | Cervix | CC | positive regulation of endopeptidase activity | 48/2311 | 179/18723 | 1.12e-07 | 5.71e-06 | 48 |
GO:00075689 | Cervix | CC | aging | 75/2311 | 339/18723 | 2.75e-07 | 1.13e-05 | 75 |
GO:00316689 | Cervix | CC | cellular response to extracellular stimulus | 59/2311 | 246/18723 | 3.03e-07 | 1.24e-05 | 59 |
GO:004254210 | Cervix | CC | response to hydrogen peroxide | 40/2311 | 146/18723 | 6.79e-07 | 2.46e-05 | 40 |
GO:00310988 | Cervix | CC | stress-activated protein kinase signaling cascade | 58/2311 | 247/18723 | 8.02e-07 | 2.89e-05 | 58 |
GO:00719007 | Cervix | CC | regulation of protein serine/threonine kinase activity | 75/2311 | 359/18723 | 2.76e-06 | 8.02e-05 | 75 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501055 | Oral cavity | EOLP | Alzheimer disease | 87/1218 | 384/8465 | 5.79e-06 | 3.67e-05 | 2.16e-05 | 87 |
hsa0472252 | Oral cavity | EOLP | Neurotrophin signaling pathway | 36/1218 | 119/8465 | 6.23e-06 | 3.87e-05 | 2.28e-05 | 36 |
hsa0501655 | Oral cavity | EOLP | Huntington disease | 69/1218 | 306/8465 | 6.32e-05 | 2.96e-04 | 1.75e-04 | 69 |
hsa0401033 | Oral cavity | EOLP | MAPK signaling pathway | 68/1218 | 302/8465 | 7.48e-05 | 3.40e-04 | 2.01e-04 | 68 |
hsa0471455 | Oral cavity | EOLP | Thermogenesis | 54/1218 | 232/8465 | 1.66e-04 | 7.16e-04 | 4.22e-04 | 54 |
hsa0453038 | Oral cavity | EOLP | Tight junction | 39/1218 | 169/8465 | 1.52e-03 | 5.34e-03 | 3.15e-03 | 39 |
hsa0152432 | Oral cavity | EOLP | Platinum drug resistance | 18/1218 | 73/8465 | 1.35e-02 | 3.53e-02 | 2.08e-02 | 18 |
hsa0501752 | Oral cavity | EOLP | Spinocerebellar ataxia | 30/1218 | 143/8465 | 1.96e-02 | 4.94e-02 | 2.91e-02 | 30 |
hsa0501262 | Oral cavity | NEOLP | Parkinson disease | 78/1112 | 266/8465 | 1.34e-12 | 1.06e-10 | 6.68e-11 | 78 |
hsa0520863 | Oral cavity | NEOLP | Chemical carcinogenesis - reactive oxygen species | 68/1112 | 223/8465 | 5.39e-12 | 2.86e-10 | 1.80e-10 | 68 |
hsa0501462 | Oral cavity | NEOLP | Amyotrophic lateral sclerosis | 95/1112 | 364/8465 | 8.76e-12 | 3.98e-10 | 2.50e-10 | 95 |
hsa0501062 | Oral cavity | NEOLP | Alzheimer disease | 97/1112 | 384/8465 | 3.97e-11 | 1.57e-09 | 9.89e-10 | 97 |
hsa0493263 | Oral cavity | NEOLP | Non-alcoholic fatty liver disease | 51/1112 | 155/8465 | 1.26e-10 | 3.84e-09 | 2.41e-09 | 51 |
hsa0502262 | Oral cavity | NEOLP | Pathways of neurodegeneration - multiple diseases | 112/1112 | 476/8465 | 1.33e-10 | 3.84e-09 | 2.41e-09 | 112 |
hsa0501662 | Oral cavity | NEOLP | Huntington disease | 75/1112 | 306/8465 | 2.92e-08 | 5.34e-07 | 3.36e-07 | 75 |
hsa0414162 | Oral cavity | NEOLP | Protein processing in endoplasmic reticulum | 49/1112 | 174/8465 | 9.02e-08 | 1.37e-06 | 8.59e-07 | 49 |
hsa0541863 | Oral cavity | NEOLP | Fluid shear stress and atherosclerosis | 40/1112 | 139/8465 | 7.44e-07 | 9.10e-06 | 5.72e-06 | 40 |
hsa0407161 | Oral cavity | NEOLP | Sphingolipid signaling pathway | 36/1112 | 121/8465 | 1.11e-06 | 1.21e-05 | 7.64e-06 | 36 |
hsa0471462 | Oral cavity | NEOLP | Thermogenesis | 56/1112 | 232/8465 | 2.86e-06 | 2.75e-05 | 1.73e-05 | 56 |
hsa0472261 | Oral cavity | NEOLP | Neurotrophin signaling pathway | 31/1112 | 119/8465 | 1.06e-04 | 7.67e-04 | 4.82e-04 | 31 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP3K5 | SNV | Missense_Mutation | rs771379166 | c.3427C>T | p.Arg1143Trp | p.R1143W | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAP3K5 | SNV | Missense_Mutation | | c.1276N>A | p.Glu426Lys | p.E426K | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AC-A2B8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | chemo | PD |
MAP3K5 | SNV | Missense_Mutation | | c.3040C>T | p.Arg1014Trp | p.R1014W | Q99683 | protein_coding | deleterious(0.02) | probably_damaging(0.993) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP3K5 | SNV | Missense_Mutation | | c.702N>C | p.Leu234Phe | p.L234F | Q99683 | protein_coding | tolerated(0.08) | possibly_damaging(0.883) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP3K5 | SNV | Missense_Mutation | novel | c.1307N>A | p.Ala436Glu | p.A436E | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0FZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAP3K5 | SNV | Missense_Mutation | novel | c.1531N>T | p.Leu511Phe | p.L511F | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0B7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
MAP3K5 | SNV | Missense_Mutation | novel | c.2311N>A | p.Gly771Ser | p.G771S | Q99683 | protein_coding | deleterious(0) | possibly_damaging(0.896) | TCGA-BH-A0BL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
MAP3K5 | SNV | Missense_Mutation | | c.1276G>A | p.Glu426Lys | p.E426K | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
MAP3K5 | SNV | Missense_Mutation | novel | c.3817G>A | p.Ala1273Thr | p.A1273T | Q99683 | protein_coding | tolerated(0.79) | benign(0.257) | TCGA-E2-A14R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
MAP3K5 | SNV | Missense_Mutation | novel | c.850C>G | p.Arg284Gly | p.R284G | Q99683 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | | GS-4997 | SELONSERTIB | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 249565756 | | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | | GS-4977 | | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 249565813 | | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 385612190 | | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | CHEMBL3545429 | SELONSERTIB | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | | hydroxyurea | HYDROXYUREA | 23556445 |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 315661125 | SELONSERTIB | |
4217 | MAP3K5 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 404859049 | | |